New options for weight management are now available. In early 2026, the FDA approved two oral (pill) medications. These medications are part of a group called GLP-1 receptor agonists. They work by mimicking natural hormones that affect appetite and digestion.
Here’s what’s new—and how these options fit into the broader picture of weight management care.
Wegovy® pill (oral semaglutide)
FDA approved: January 2026
Type: Oral GLP-1 receptor agonist
How you take it: Once daily
The Wegovy® pill is a higher-dose tablet containing semaglutide, the same active ingredient as the Wegovy® injections. You should take it on an empty stomach with a small sip of water at least 30 minutes before eating or drinking.
Foundayo® (orforglipron)
FDA approved: April 1, 2026
Type: Oral GLP-1 receptor agonist
How you take it: Once daily
Foundayo is a “non-peptide” medication, which means it’s less affected by stomach acid. Because of this, it can be taken with or without food, at any time of day.
The FDA approved both medications for adults who:
Have a BMI of 30 or higher
or
Have a BMI of 27 or higher, and at least one related condition, such as:
type 2 diabetes
high blood pressure
high cholesterol
sleep apnea
They are most effective if paired with a healthy diet and regular physical activity.
There are now two ways to take medications in this category: daily pills and weekly injections. Both target similar pathways in the body, but the experience of taking them is different.
| Oral medications (pills) | Injectable medications | |
| Frequency | Once daily | Once weekly |
| How it’s taken | By mouth | Self-administered injection |
| When to take it | Foundayo (flexible); Wegovy pill (empty stomach required) | Can be taken at any time of day |
| How the body absorbs it | Through the digestive system | Directly into the bloodstream |
| Costs (self-pay/cash) | From $149 (starting dose) and $299 (higher dose) | From $199 (starting dose) to $499 (higher dose) |
In clinical trials lasting about 70 weeks, both medications were associated with meaningful weight loss when combined with lifestyle changes:
Foundayo (orforglipron): About 11% average weight loss
Wegovy pill (oral semaglutide 50 mg): Up to 14% average weight loss
Results vary from person to person. These medications are designed to support long-term weight management.
Side effects are similar to those of other medications in this class. Because they slow digestion, the most common ones include:
Nausea
Vomiting
Diarrhea or constipation
These symptoms are often more noticeable when starting or adjusting the dose. Many people find they improve over time.
Weight management looks different for everyone. These medications can be one part of a broader plan that may include nutrition, movement, sleep, and ongoing support. What works well for one person may not feel right for another—and that’s okay.
If you’re curious about these new options, your Care Team can help you understand what’s available and how it fits into your care. They can help you understand:
What medication works best for you
Understand how each medication is taken
Talk through what to expect over time
Reach out anytime via chat or email to start the conversation.